News Could OMass become the UK's 'big biotech' company? UK-based OMass Therapeutics' ambition to join the 'big biotech' ranks has been bolstered by an impressive $310m third-round financing.
News OMass attracts $420m Roche wager on IBD programme UK biotech OMass has revealed its first major pharma partnership, with Roche paying $20m upfront for an inflammatory bowel disease programme.
News Google, Sanofi back UK biotech OMass' $100m second round OMass Therapeutics has raised an impressive $100 million in a Series B financing that is said to be the largest ever for a UK biotech focusing on small-molecule drug development.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.